Document is current
Any future updates will be listed below
-
Authors
Vetterlein, Julia
Doehmen, Cornelius A. E.
Voss, Holger
Dittkrist, Luisa
Klapp, Christine
Henrich, Wolfgang
Ramsauer, Babett
Schlembach, Dietmar
Abou-Dakn, Michael
Maresh, Michael J. A.
Schaefer-Graf, Ute M. https://orcid.org/0000-0002-3545-8009
- License Information
-
More Information
Article History
Received: 8 December 2020
Accepted: 17 March 2021
First Online: 13 August 2021
Declaration
:
: UMS-G received remuneration for lectures by pharmaceutical companies (Novo Nordisk, Berlin-Chemie, Sanofi-Aventis). MJAM received an honorarium from Novo Nordisk for chairing the Drug Monitoring Committee on a trial comparing two of their long-acting insulins in type 1 diabetes. The remaining authors report no conflict of interest. The contributing authors are solely responsible for the content of the manuscript.
: This study was performed in line with the principles of the Declaration of Helsinki and received ethical approval (Eth-33/16 Berlin Medical Association).
: The need for individual written consent was waived by the local Ethics Committee of Berlin Medical Association in view of the retrospective nature of the study. All data were stored and analyzed anonymously.
